Stathmin 1 expression in neuroendocrine and proliferating prostate cancer
Abstract Prostate cancer (PCa) is the second leading cause of cancer-related mortality among men in the United States. While PCa initially responds to androgen deprivation therapy, a significant portion progresses to castration-resistant PCa. Approximately 20–25% of these cases acquire aggressive ne...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-01-01
|
| Series: | Discover Oncology |
| Online Access: | https://doi.org/10.1007/s12672-025-01754-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841544536086544384 |
|---|---|
| author | Yingli Shi Yunshin A. Yeh Siyuan Cheng Xin Gu Shu Yang Lin Li Nazih P. Khater Susan Kasper Xiuping Yu |
| author_facet | Yingli Shi Yunshin A. Yeh Siyuan Cheng Xin Gu Shu Yang Lin Li Nazih P. Khater Susan Kasper Xiuping Yu |
| author_sort | Yingli Shi |
| collection | DOAJ |
| description | Abstract Prostate cancer (PCa) is the second leading cause of cancer-related mortality among men in the United States. While PCa initially responds to androgen deprivation therapy, a significant portion progresses to castration-resistant PCa. Approximately 20–25% of these cases acquire aggressive neuroendocrine (NE) features, ultimately leading to neuroendocrine prostate cancer (NEPC). In this study, we investigated the expression of stathmin 1 (STMN1) across PCa subtypes using bioinformatics, western blotting, and immunohistochemical staining analyses in human and murine models. We found that elevated STMN1 expression correlated with high Gleason Scores, increased cell proliferation, and poor clinical outcomes in PCa patients. Notably, STMN1 expression was significantly higher in NEPC compared to prostate adenocarcinoma, suggesting its role in NEPC progression. Findings from TRAMP tumors, a murine NEPC model, further supported these results. In conclusion, STMN1 expression is elevated in advanced PCa, particularly in NEPC, suggesting its involvement in the progression of aggressive forms of PCa. While STMN1 shows potential as a diagnostic and prognostic marker for aggressive PCa, further studies are necessary to establish its clinical utility. |
| format | Article |
| id | doaj-art-aa5488cd79f44b10b43d31cf0b7591ba |
| institution | Kabale University |
| issn | 2730-6011 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Springer |
| record_format | Article |
| series | Discover Oncology |
| spelling | doaj-art-aa5488cd79f44b10b43d31cf0b7591ba2025-01-12T12:29:16ZengSpringerDiscover Oncology2730-60112025-01-0116111310.1007/s12672-025-01754-6Stathmin 1 expression in neuroendocrine and proliferating prostate cancerYingli Shi0Yunshin A. Yeh1Siyuan Cheng2Xin Gu3Shu Yang4Lin Li5Nazih P. Khater6Susan Kasper7Xiuping Yu8Department of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center at ShreveportPathology and Laboratory Medicine Service, Overton Brooks VA Medical CenterDepartment of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center at ShreveportDepartment of Pathology, Louisiana State University Health Sciences Center at ShreveportDepartment of Bone Marrow Transplant, Ochsner LSU HealthDepartment of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center at ShreveportDepartment of Urology, Louisiana State University Health Sciences Center at ShreveportDepartment of Environmental and Public Health Sciences, University of Cincinnati College of MedicineDepartment of Biochemistry and Molecular Biology, Louisiana State University Health Sciences Center at ShreveportAbstract Prostate cancer (PCa) is the second leading cause of cancer-related mortality among men in the United States. While PCa initially responds to androgen deprivation therapy, a significant portion progresses to castration-resistant PCa. Approximately 20–25% of these cases acquire aggressive neuroendocrine (NE) features, ultimately leading to neuroendocrine prostate cancer (NEPC). In this study, we investigated the expression of stathmin 1 (STMN1) across PCa subtypes using bioinformatics, western blotting, and immunohistochemical staining analyses in human and murine models. We found that elevated STMN1 expression correlated with high Gleason Scores, increased cell proliferation, and poor clinical outcomes in PCa patients. Notably, STMN1 expression was significantly higher in NEPC compared to prostate adenocarcinoma, suggesting its role in NEPC progression. Findings from TRAMP tumors, a murine NEPC model, further supported these results. In conclusion, STMN1 expression is elevated in advanced PCa, particularly in NEPC, suggesting its involvement in the progression of aggressive forms of PCa. While STMN1 shows potential as a diagnostic and prognostic marker for aggressive PCa, further studies are necessary to establish its clinical utility.https://doi.org/10.1007/s12672-025-01754-6 |
| spellingShingle | Yingli Shi Yunshin A. Yeh Siyuan Cheng Xin Gu Shu Yang Lin Li Nazih P. Khater Susan Kasper Xiuping Yu Stathmin 1 expression in neuroendocrine and proliferating prostate cancer Discover Oncology |
| title | Stathmin 1 expression in neuroendocrine and proliferating prostate cancer |
| title_full | Stathmin 1 expression in neuroendocrine and proliferating prostate cancer |
| title_fullStr | Stathmin 1 expression in neuroendocrine and proliferating prostate cancer |
| title_full_unstemmed | Stathmin 1 expression in neuroendocrine and proliferating prostate cancer |
| title_short | Stathmin 1 expression in neuroendocrine and proliferating prostate cancer |
| title_sort | stathmin 1 expression in neuroendocrine and proliferating prostate cancer |
| url | https://doi.org/10.1007/s12672-025-01754-6 |
| work_keys_str_mv | AT yinglishi stathmin1expressioninneuroendocrineandproliferatingprostatecancer AT yunshinayeh stathmin1expressioninneuroendocrineandproliferatingprostatecancer AT siyuancheng stathmin1expressioninneuroendocrineandproliferatingprostatecancer AT xingu stathmin1expressioninneuroendocrineandproliferatingprostatecancer AT shuyang stathmin1expressioninneuroendocrineandproliferatingprostatecancer AT linli stathmin1expressioninneuroendocrineandproliferatingprostatecancer AT nazihpkhater stathmin1expressioninneuroendocrineandproliferatingprostatecancer AT susankasper stathmin1expressioninneuroendocrineandproliferatingprostatecancer AT xiupingyu stathmin1expressioninneuroendocrineandproliferatingprostatecancer |